Allarity Therapeutics, Inc.
ALLRNasdaq
$1.19
↑ +1.7%Jul 17 close · end-of-day
Price
1Y↑ +19.0%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$11.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-162.6%
ROIC
-134.7%
Debt / Equity
2.9
Net Cash
-$268,000.00
Return 1Y
+19.0%
Company profile
N/A
- CEO
- James G. Cullem
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- Massachusetts
- Website
- allarity.com
Management & directors
- Ervin Jeffrey SCFO
- Graff Jeremy R.See Remarks
- Jensen ThomasCEO
Roles derived from SEC Form 4 filings.
Earnings
ALLR Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$25,000.00—
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0.00 | $320,000.00 |
| Gross profit | — | — | -$2.3M | — | — | — |
| Operating income | -$8.3M | -$26.6M | -$34.5M | -$17.1M | -$27.2M | -$12.6M |
| Net income | -$6.6M | -$26.6M | -$16.1M | -$11.9M | -$24.5M | -$11.2M |
| Diluted EPS | — | -$4.19 | -$3,093.42 | -$10.26 | — | — |
| Operating cash flow | -$7.3M | -$14.9M | -$16.8M | -$12.7M | -$17.4M | -$14.8M |
| Free cash flow | -$7.3M | — | -$16.8M | -$12.7M | -$17.6M | -$14.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | -3939.1% |
| Net margin | — | — | — | — | — | -3509.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | — | — | — | $25,000.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.4M | -$12.3M | -$7.3M | -$3.0M | -$4.1M | -$2.5M | -$2.9M | -$2.7M |
| Net income | -$1.6M | -$11.6M | -$7.5M | -$2.7M | -$2.3M | -$2.8M | -$3.4M | -$2.8M |
| Diluted EPS | -$0.11 | — | — | — | — | — | — | — |
| Operating cash flow | -$7.3M | -$5.4M | -$3.2M | -$2.7M | -$5.5M | -$3.4M | -$3.2M | -$4.5M |
| Free cash flow | — | — | — | -$2.7M | — | — | — | -$4.6M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | -10752.0% |
| Net margin | — | — | — | — | — | — | — | -11000.0% |
Company news
Jun 19, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-01-28 | Jensen Thomas· CEO | Award | 200,000 | $0.00 | $0.00 | filing |
| 2026-01-28 | McLaughlin Gerald W. | Award | 45,000 | $0.00 | $0.00 | filing |
| 2026-01-28 | Graff Jeremy R.· See Remarks | Award | 133,333 | $0.00 | $0.00 | filing |
| 2026-01-28 | Ervin Jeffrey S· CFO | Award | 150,000 | $0.00 | $0.00 | filing |
| 2026-01-07 | Hoiland Jesper | Award | 25,000 | $0.00 | $0.00 | filing |
| 2026-01-07 | Graff Jeremy R.· See Remarks | Award | 133,333 | $0.00 | $0.00 | filing |
| 2025-09-30 | Graff Jeremy R.· See Remarks | Tax withholding | 14,613 | $1.58 | $23,088.54 | filing |
| 2025-09-30 | Graff Jeremy R.· See Remarks | Option exercise | 39,494 | — | — | filing |
Latest 8 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.